Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00025259 · ClinicalTrials.gov registry record · Phase 3

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

A Phase 3 study, sponsored by Children's Oncology Group.

Completed
Registry status
Phase 3
Development phase
1,734
Enrollment target

NCT00025259 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 1,734 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00025259, a Phase 3 study, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status
Phase 3
Development phase
1,734 participants
Enrollment target

Study Summary

This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.

Interventions

  • DRUG Cyclophosphamide
  • DRUG Cisplatin
  • DRUG Dexamethasone
  • BIOLOGICAL Bleomycin Sulfate
  • DRUG Cytarabine

Trial Details

FieldValue
Enrollment Target 1,734 participants
Start Date 2002-09
Phase Phase 3

Sponsor

Children's Oncology Group

342 total trials

What the Registry Record Tells You About NCT00025259

The ClinicalTrials.gov registry entry for NCT00025259 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,734 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT00025259 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00025259 about?

NCT00025259 is a clinical study titled "Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease". This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop...

What is the current status of trial NCT00025259?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,734 participants. The study started on 2002-09.

What interventions are being tested in trial NCT00025259?

The interventions under investigation include: Cyclophosphamide (DRUG), Cisplatin (DRUG), Dexamethasone (DRUG), Bleomycin Sulfate (BIOLOGICAL), Cytarabine (DRUG).

Who is sponsoring clinical trial NCT00025259?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.